Want to see TRAW full AI Analyst Report?
TRAW Stock Chart & Stats
$0.60
-$0.03(-6.13%)
At close: 4:00 PM EDT
$0.60
-$0.03(-6.13%)
Day’s Range― - ―
52-Week Range$0.43 - $3.27
Previous CloseN/A
Volume182.49K
Average Volume (3M)1.07M
Market Cap
$8.74M
Enterprise Value$8.37M
Total Cash (Recent Filing)$3.13M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.52
Next Earnings
Nov 12, 2026EPS Estimate
-0.21Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.61
Shares Outstanding15,368,277
10 Day Avg. Volume3,070,542
30 Day Avg. Volume1,074,599
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)-14.78
Price to Sales (P/S)3.33
P/FCF Ratio-0.45
Enterprise Value/Market Cap0.96
Enterprise Value/Revenue3.06
Enterprise Value/Gross Profit3.06
Enterprise Value/Ebitda-0.54
Forecast
1Y Price Target
$1.00Price Target Upside66.67% Upside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)-1.43
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-Free Balance SheetNo debt reduces refinancing pressure and fixed repayment obligations while the company funds clinical development. Despite negative equity, the absence of leverage preserves some financial flexibility and may allow management to structure future capital needs without servicing debt.
Lead Program AdvancementProgress on the lead influenza program provides a tangible route toward clinical validation and potential future value creation. Preparing a revised toxicology package and pursuing a Phase 2a study show continued development execution despite regulatory work still required.
Near-Term Funding AccessThe private placement and ATM program provide capital access to support operations and advance development over the next several months. Extending the expected runway into early 2027 gives management time to pursue regulatory milestones before seeking additional financing.
Bears Say
Persistent Cash Burn And Negative EquityPersistent operating and free-cash-flow losses show that the company is consuming cash rather than self-funding. The major 2025 deterioration and negative equity weaken the capital base, increasing dependence on external financing to sustain research and operations.
Regulatory Development DelaysThe influenza program remains exposed to regulatory execution risk because the U.S. IND is on clinical hold and the UK package must be revised before Phase 2a. These requirements can delay human studies, extend development timelines, and postpone clinical validation.
Nasdaq Listing Compliance RiskThe minimum bid price deficiency creates a meaningful corporate risk because failure to restore compliance by January 25, 2027 could lead to further Nasdaq action and possible delisting proceedings. This may complicate access to public-market financing and investor participation.
Traws Pharma News
TRAW FAQ
What was Traws Pharma’s price range in the past 12 months?
Traws Pharma lowest stock price was $0.43 and its highest was $3.27 in the past 12 months.
What is Traws Pharma’s market cap?
Traws Pharma’s market cap is $8.74M.
When is Traws Pharma’s upcoming earnings report date?
Traws Pharma’s upcoming earnings report date is Nov 12, 2026 which is in 39 days.
How were Traws Pharma’s earnings last quarter?
Traws Pharma released its earnings results on Aug 14, 2026. The company reported -$0.16 earnings per share for the quarter, beating the consensus estimate of -$0.335 by $0.175.
Is Traws Pharma overvalued?
According to Wall Street analysts Traws Pharma’s price is currently Undervalued.
Does Traws Pharma pay dividends?
Traws Pharma does not currently pay dividends.
What is Traws Pharma’s EPS estimate?
Traws Pharma’s EPS estimate is -0.21.
How many shares outstanding does Traws Pharma have?
Traws Pharma has 15,368,277 shares outstanding.
What happened to Traws Pharma’s price movement after its last earnings report?
Traws Pharma reported an EPS of -$0.16 in its last earnings report, beating expectations of -$0.335. Following the earnings report the stock price went down -5.429%.
Which hedge fund is a major shareholder of Traws Pharma?
Currently, no hedge funds are holding shares in TRAW
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Traws Pharma
Traws Pharma, Inc., a biopharmaceutical firm in the clinical development stage, is dedicated to creating novel small-molecule medications delivered orally to combat both respiratory viral infections and various forms of cancer. Its pipeline includes experimental treatments specifically designed to overcome drug resistance in influenza and COVID-19. These promising candidates include TRX01 (travatrelvir), an Mpro/3CL inhibitor currently undergoing development for COVID-19, and TRX100 (viroxavir), an endonuclease inhibitor advancing through trials for pandemic influenza. Additionally, Traws Pharma's oncology portfolio features narazaciclib, a multi-kinase CDK4/6 inhibitor. This compound is presently in Phase 1/2 clinical trials in cancer patients, being evaluated both independently and in conjunction with letrozole, with the goal of establishing the recommended Phase 2 dosage for future work in endometrial cancer. The company is also investigating oral rigosertib, exploring its potential as a standalone therapy or in combination regimens across diverse cancer types. Originally established in 1998 as Onconova Therapeutics, Inc., the company officially adopted its current name, Traws Pharma, Inc., in April 2024. Its corporate headquarters are located in Newtown, Pennsylvania.
TRAW Stock 12 Month Forecast
Average Price Target
$1.00
▲(66.67% Upside)
Technical Analysis
Ownership Overview
12.38% Insiders
0.73% Mutual Funds
33.07% Other Institutional Investors
51.67% Public Companies and
Individual Investors